[Immunotherapy in the context of other head and neck cancer treatment modalities-highlights of the ASCO and ESMO annual meeting 2022]. / Immuntherapie im Kontext anderer Therapiemodalitäten von Kopf-Hals-Tumoren ­ Highlights der ASCO- und ESMO-Jahrestagung 2022.

ABSTRACT

Immunotherapeutic agents are nowadays established for treatment of a wide variety of tumor entities, including squamous cell carcinoma of the head and neck region. Originally used in the palliative setting, these are increasingly administered with curative intent, e.g., as neoadjuvant treatment. Current research addresses the questions of which patients benefit from the treatment and which combination therapies are successful. The present article summarizes relevant findings of the two international cancer congresses in 2022.